Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

24,258 signal articles · 46 in last 24h · 115,243 total before filter · latest 1h ago
46last 24h
1804last 7d
299● bullish (7d)
171● bearish (7d)
205publishers
AllMacro322Earnings851M&A105Regulatory25Product16Analyst25
✕ clear all filtersticker: WFCsentiment: bullishSentiment:bullishneutralbearishshow all (incl. clickbait)
Earnings Are Beating Wall Street’s Boldest Expectations. What Comes Next.
Barrons.com4d agobullish
Earnings Are Beating Wall Street’s Boldest Expectations. What Comes Next.

There’s an elegant simplicity to one of the central tenets in gauging the health of the stock market and the companies that comprise its benchmark indexes: figuring out what’s in the till at the end of the day. Profit remains the most important measure of stock market health—and Corporate America is raking it in. “The greatest force behind stock markets right now is earnings, which is helping to overshadow concerns about Iran, inflation and AI [capital expenditure] spending viability,” said Dennis Follmer, chief investment officer, at Montis Financial in Waltham, Mass., to Barron’s. “Earnings have been an absolute freight train driving this market higher.”

Bloomberg22d agobullish
Eli Lilly-Backed Scribe Therapeutics Jumps 67% After Upsized IPO

(Bloomberg) -- Scribe Therapeutics Inc., a clinical-stage developer of gene therapies for heart diseases, surged 67% on Friday after raising $128.7 million in an upsized initial public offering.Most Read from BloombergRetina Chip Designed to Restore Sight to Go on Sale in EuropeHegseth Turns to UNC, Virginia Tech After Dropping Ivy LeagueApple Plans Overhaul of MacBooks, iMac in Push to Meet AI DemandTrump Rebuilds Tariffs With New Levies on 60 EconomiesSpaceX Turns Away Falcon Customers in Majo